[ad_1]
Novavax (NVAX) recorded a quarterly loss of $ 0.11 per share, compared to a loss of $ 0.12, according to the Zacks consensus estimate. This compares to a loss of $ 0.14 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents a profit surprise of 8.33%. A quarter of a month ago, it was expected that the vaccine maker would record a loss of $ 0.12 per share while producing a loss of $ 0.13, a surprise -8.33%.
In the last four quarters, the company has exceeded EPS consensus estimates only once.
Novavax, which belongs to the Zacks Medical – Biomedical and Genetics sector, achieved a turnover of $ 3.98 million for the quarter ended March 31, 2019, or 17.04% of the advance on the Estimate by consensus of Zacks. This compares with revenues of $ 9.65 million a year ago. The company has surpassed consensus business estimates only once in the last four quarters.
The sustainability of the immediate movement of stock prices, based on recently published figures and future earnings forecasts, will depend primarily on management's feedback on the earnings call.
Novavax shares have lost about 72% since the beginning of the year, compared to 16.6% for the S & P 500.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "What's next for Novavax?"data-reactid =" 28 ">What's next for Novavax?
While Novavax has underperformed the market since the beginning of the year, the question for investors is: what is the next step for the stock?
There is no easy answer to this key question, but the company's earnings outlook is a reliable measure to help investors. This includes not only the forecast of current consensus results for the coming quarters, but also the way in which these forecasts have changed recently.
Empirical research shows a strong correlation between short-term stock movements and trends in revisions to earnings estimates. Investors can track these revisions themselves, or rely on a proven scoring tool such as Zacks Rank, which has impressive experience operating the revision of earnings power estimates.
Prior to the release of these results, the trend of estimated revisions for Novavax was mixed. Although the magnitude and direction of the revisions may change as a result of the release of the company's earnings report, the current status results in a ranking of Zacks # 3 (pending) for the stock. As a result, equities should evolve in line with the market in the near future. You can see the complete list of # 1 Zacks stock at current rank (strong buy) here.
It will be interesting to see how the estimates for the coming quarters and the current fiscal year will change in the coming days. The consensus estimate of EPS is currently -0.10 USD on revenues of 3.53 million USD for the next quarter and 0.39 USD on revenues of 11.45 million USD for the next quarter. exercise in progress.
Investors should be aware that the outlook for the sector can also have a significant impact on the performance of the security. Regarding the Zacks ranking, Medical – Biomedical and Genetics is currently in the top 30 of the 250+ Zack industries. Our research shows that the top 50% of industries ranked by Zacks perform better than the bottom 50% by a factor greater than 2 to 1.
Do you want to know the latest Zacks Investment Research recommendations? Today, you can download 7 best actions for the next 30 days. Click to get this free report
Novavax, Inc. (NVAX): Free Stock Analysis Report
To read this article on Zacks.com, click here.
[ad_2]
Source link